| A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (NCT01351103) | Novartis Pharmaceuticals | 2011-12-01 |
| Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors (NCT01421004) | Novartis Pharmaceuticals | 2011-12-01 |
| A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer (NCT01217177) | Novartis Pharmaceuticals | 2011-12-01 |
| Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (NCT01412944) | Novartis Pharmaceuticals | 2011-12-01 |
| Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes (NCT01497522) | Novartis Pharmaceuticals | 2011-12-01 |
| Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects (NCT01660295) | Novartis Pharmaceuticals | 2011-12-01 |
| Efficacy of LCQ908 on Cardiovascular Risk (NCT01474434) | Novartis Pharmaceuticals | 2011-12-01 |
| A Real-World Study of Clinical Use of Available Treatments for Pediatric Patients With Spinal Muscular Atrophy (NCT07474311) | Novartis Pharmaceuticals | 2011-11-22 |
| Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease (NCT01374906) | Novartis Pharmaceuticals | 2011-11-04 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients (NCT01487460) | Novartis Pharmaceuticals | 2011-11-01 |
| Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis (NCT01490840) | Novartis Pharmaceuticals | 2011-11-01 |
| A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device (NCT01484197) | Novartis Pharmaceuticals | 2011-11-01 |
| Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma (NCT01402440) | Novartis Pharmaceuticals | 2011-11-01 |
| β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3) (NCT01470989) | Novartis Pharmaceuticals | 2011-11-01 |
| Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function (NCT01443481) | Novartis Pharmaceuticals | 2011-11-01 |
| Everolimus in de Novo Kidney Transplant Recipients (NCT01410448) | Novartis Pharmaceuticals | 2011-11-01 |
| Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (NCT01491672) | Novartis Pharmaceuticals | 2011-11-01 |
| Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients (NCT01402401) | Novartis Pharmaceuticals | 2011-11-01 |
| Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) (NCT01433354) | Novartis Pharmaceuticals | 2011-11-01 |
| Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression (NCT01436643) | Novartis Pharmaceuticals | 2011-11-01 |
| Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias (NCT01385592) | Novartis Pharmaceuticals | 2011-11-01 |
| Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis (NCT01433445) | Novartis Pharmaceuticals | 2011-11-01 |
| A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer (NCT01379534) | Novartis Pharmaceuticals | 2011-11-01 |
| The Gilenya Pregnancy Registry (NCT01285479) | Novartis Pharmaceuticals | 2011-10-15 |
| The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (NCT01490125) | Novartis Pharmaceuticals | 2011-10-01 |
| Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment (NCT01727128) | Novartis Pharmaceuticals | 2011-10-01 |
| Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia (NCT01546415) | Novartis Pharmaceuticals | 2011-10-01 |
| 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis (NCT01358175) | Novartis Pharmaceuticals | 2011-10-01 |
| Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate (NCT01359943) | Novartis Pharmaceuticals | 2011-10-01 |
| A Study of BYL719 in Adult Patients With Advanced Solid Malignancies (NCT01387321) | Novartis Pharmaceuticals | 2011-09-22 |
| Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease (NCT01474421) | Novartis Pharmaceuticals | 2011-09-15 |
| Efficacy of Indacaterol 150 µg Versus Formoterol (NCT01377428) | Novartis Pharmaceuticals | 2011-09-01 |
| Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer (NCT01338831) | Novartis Pharmaceuticals | 2011-09-01 |
| A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT01440374) | Novartis Pharmaceuticals | 2011-09-01 |
| Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (NCT01499667) | Novartis Pharmaceuticals | 2011-09-01 |
| Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients (NCT01449591) | Novartis Pharmaceuticals | 2011-09-01 |
| Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) (NCT01350804) | Novartis Pharmaceuticals | 2011-09-01 |
| Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (NCT01392326) | Novartis Pharmaceuticals | 2011-09-01 |
| Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents (NCT01377012) | Novartis Pharmaceuticals | 2011-08-30 |
| Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients (NCT01431638) | Novartis Pharmaceuticals | 2011-08-25 |
| INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (NCT01493414) | Novartis Pharmaceuticals | 2011-08-16 |
| An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. (NCT01582061) | Novartis Pharmaceuticals | 2011-08-16 |
| Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (NCT01231659) | Novartis Pharmaceuticals | 2011-08-09 |
| Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. (NCT01336634) | Novartis Pharmaceuticals | 2011-08-05 |
| Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (NCT01406938) | Novartis Pharmaceuticals | 2011-08-01 |
| Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients (NCT01447485) | Novartis Pharmaceuticals | 2011-08-01 |
| A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients (NCT01426789) | Novartis Pharmaceuticals | 2011-08-01 |
| Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies (NCT01442194) | Novartis Pharmaceuticals | 2011-08-01 |
| Dose Finding Study for QAW039 in Asthma (NCT01437735) | Novartis Pharmaceuticals | 2011-08-01 |
| Fingolimod -Response According to Coping - Evaluation (NCT01420055) | Novartis Pharmaceuticals | 2011-08-01 |
| Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) (NCT01364415) | Novartis Pharmaceuticals | 2011-08-01 |
| Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis (NCT01423110) | Novartis Pharmaceuticals | 2011-08-01 |
| Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome (NCT01348087) | Novartis Pharmaceuticals | 2011-08-01 |
| Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age (NCT01365481) | Novartis Pharmaceuticals | 2011-08-01 |
| Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas (NCT01433263) | Novartis Pharmaceuticals | 2011-08-01 |
| Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) (NCT01396083) | Novartis Pharmaceuticals | 2011-08-01 |
| A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment (NCT01232296) | Novartis Pharmaceuticals | 2011-07-01 |
| A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease (NCT01399125) | Novartis Pharmaceuticals | 2011-07-01 |
| Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox (NCT01394029) | Novartis Pharmaceuticals | 2011-07-01 |
| Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins (NCT01859455) | Novartis Pharmaceuticals | 2011-07-01 |
| A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients (NCT01387958) | Novartis Pharmaceuticals | 2011-07-01 |
| Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) (NCT01396057) | Novartis Pharmaceuticals | 2011-07-01 |
| Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects (NCT01433458) | Novartis Pharmaceuticals | 2011-07-01 |
| Sickle Cell Disease: A Retrospective Chart Review (NCT01441375) | Novartis Pharmaceuticals | 2011-07-01 |
| A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma (NCT01327053) | Novartis Pharmaceuticals | 2011-06-29 |
| Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective (NCT01362608) | Novartis Pharmaceuticals | 2011-06-20 |
| A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients (NCT01355614) | Novartis Pharmaceuticals | 2011-06-01 |
| Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (NCT01365455) | Novartis Pharmaceuticals | 2011-06-01 |
| Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC (NCT01379521) | Novartis Pharmaceuticals | 2011-06-01 |
| Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET (NCT01374451) | Novartis Pharmaceuticals | 2011-06-01 |
| Phase II BGG492 Capsule Extension for Partial Epilepsy (NCT01338805) | Novartis Pharmaceuticals | 2011-06-01 |
| Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM) (NCT01407003) | Novartis Pharmaceuticals | 2011-06-01 |
| Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy (NCT01398592) | Novartis Pharmaceuticals | 2011-06-01 |
| Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (NCT01358578) | Novartis Pharmaceuticals | 2011-06-01 |
| A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor (NCT01390519) | Novartis Pharmaceuticals | 2011-06-01 |
| Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion (NCT01377597) | Novartis Pharmaceuticals | 2011-06-01 |
| Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) (NCT01392495) | Novartis Pharmaceuticals | 2011-06-01 |
| Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) (NCT01294579) | Novartis Pharmaceuticals | 2011-05-17 |
| Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients (NCT01320358) | Novartis Pharmaceuticals | 2011-05-10 |
| A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer (NCT01160211) | Novartis Pharmaceuticals | 2011-05-05 |
| Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (NCT01317004) | Novartis Pharmaceuticals | 2011-05-01 |
| Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms (NCT01333501) | Novartis Pharmaceuticals | 2011-05-01 |
| Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma (NCT01302886) | Novartis Pharmaceuticals | 2011-05-01 |
| LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension (NCT01373086) | Novartis Pharmaceuticals | 2011-05-01 |
| A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome (NCT01428297) | Novartis Pharmaceuticals | 2011-05-01 |
| Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes (NCT01368536) | Novartis Pharmaceuticals | 2011-05-01 |
| Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome (NCT01357239) | Novartis Pharmaceuticals | 2011-05-01 |
| Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients (NCT01356602) | Novartis Pharmaceuticals | 2011-05-01 |
| Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations (NCT01460862) | Novartis Pharmaceuticals | 2011-05-01 |
| Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer (NCT01297491) | Novartis Pharmaceuticals | 2011-05-01 |
| A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects (NCT01456663) | Novartis Pharmaceuticals | 2011-05-01 |
| An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) (NCT01595009) | Novartis Pharmaceuticals | 2011-04-27 |
| Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants (NCT01392469) | Novartis Pharmaceuticals | 2011-04-20 |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia (NCT01313689) | Novartis Pharmaceuticals | 2011-04-14 |
| A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) (NCT01077544) | Novartis Pharmaceuticals | 2011-04-14 |
| Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) (NCT01327846) | Novartis Pharmaceuticals | 2011-04-11 |
| Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes (NCT01356381) | Novartis Pharmaceuticals | 2011-04-01 |
| RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation (NCT01317615) | Novartis Pharmaceuticals | 2011-04-01 |
| Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients (NCT01254188) | Novartis Pharmaceuticals | 2011-04-01 |
| Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) (NCT01350115) | Novartis Pharmaceuticals | 2011-04-01 |